-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Anakinra is a human interleukin-1 receptor antagonist produced by genetic recombination technology
Anakinra is a human interleukin-1 receptor antagonist produced by genetic recombination technology
This is a multicenter, randomized, double-blind study to include not suitable for use in patients with non-steroidal anti-inflammatory drugs and colchicine treatment, follow-up of 2 years
The results are as follows: 165 patients were enrolled , including anakinra (n = 110) or triamcinolone acetonide (n = 55)
The results are as follows: 165 patients were enrolled , including anakinra (n = 110) or triamcinolone acetonide (n = 55)
It can be seen that anakinra is not superior to triamcinolone acetonide in terms of the primary endpoint, but its pain reduction effect is equivalent to that of triamcinolone acetonide, and it performs better in most secondary endpoints
Original source:
Original source: Original source:Kenneth G.
Kenneth G.
Saag.
A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares.
Arthritis Rheumatol.
August 2021.
A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares .
in this message